XTSEAVCN
Market cap22mUSD
Dec 24, Last price
0.32CAD
1D
0.00%
1Q
-15.79%
IPO
-95.36%
Name
Avicanna Inc
Chart & Performance
P/E
—
P/S
2.10
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
40.18%
Rev. gr., 5y
169.56%
Revenues
17m
+314.82%
Net income
-9m
L-40.67%
CFO
-1m
L-81.11%
Earnings
Mar 31, 2025
Profile
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 16,791 314.82% | 4,048 23.83% | 3,269 108.20% | |||||
Cost of revenue | 23,964 | 13,195 | 13,620 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (7,173) | (9,148) | (10,351) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 1,503 | 14 | ||||||
Tax Rate | ||||||||
NOPAT | (7,173) | (10,651) | (10,365) | |||||
Net income | (8,743) -40.67% | (14,735) -12.16% | (16,775) -48.95% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 2,084 | 9,076 | 9,091 | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 1,708 | 2,808 | 1,246 | |||||
Long-term debt | 341 | 774 | 572 | |||||
Deferred revenue | 1,938 | 2,354 | 2,782 | |||||
Other long-term liabilities | (180) | (416) | ||||||
Net debt | 1,572 | 2,388 | 1,607 | |||||
| Cash flow | ||||||||
Cash from operating activities | (1,404) | (7,435) | (11,663) | |||||
CAPEX | (45) | (67) | (789) | |||||
Cash from investing activities | (3,047) | 810 | 761 | |||||
Cash from financing activities | 3,554 | 9,901 | 10,060 | |||||
FCF | (8,511) | (8,632) | (3,706) | |||||
| Balance | ||||||||
Cash | 477 | 1,194 | 31 | |||||
Long term investments | 180 | |||||||
Excess cash | 992 | 48 | ||||||
Stockholders' equity | 7,972 | (15,064) | (9,561) | |||||
Invested Capital | 11,713 | 23,906 | 20,498 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 84,708 | 59,167 | 41,285 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (6,396) | (8,260) | (9,457) | |||||
EV/EBITDA | ||||||||
Interest | 610 | 1,672 | 738 | |||||
Interest/NOPBT | ||||||||